These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 20688444)

  • 1. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions.
    Pery C; Meurette G; Ansquer C; Frampas E; Regenet N
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):465-74. PubMed ID: 20688444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
    Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
    ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.
    Nguyen VX; Nguyen CC; Nguyen BD
    JOP; 2011 Nov; 12(6):557-66. PubMed ID: 22072244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.
    Bares R; Klever P; Hauptmann S; Hellwig D; Fass J; Cremerius U; Schumpelick V; Mittermayer C; Büll U
    Radiology; 1994 Jul; 192(1):79-86. PubMed ID: 8208970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
    Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
    J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
    Saif MW; Cornfeld D; Modarresifar H; Ojha B
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT.
    Toshikuni N; Kai K; Fujisawa M
    Ann Nucl Med; 2008 Feb; 22(2):133-7. PubMed ID: 18311538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of positron emission tomography in the management of pancreatic cancer.
    Pakzad F; Groves AM; Ell PJ
    Semin Nucl Med; 2006 Jul; 36(3):248-56. PubMed ID: 16762614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (18)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors.
    Luo G; Liu Z; Guo M; Jin K; Xiao Z; Liu L; Xu J; Zhang B; Liu C; Huang D; Hu S; Ni Q; Long J; Yu X
    Int J Oncol; 2014 Oct; 45(4):1531-6. PubMed ID: 25096059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
    Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
    World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.
    Farma JM; Santillan AA; Melis M; Walters J; Belinc D; Chen DT; Eikman EA; Malafa M
    Ann Surg Oncol; 2008 Sep; 15(9):2465-71. PubMed ID: 18551347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
    Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
    Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma].
    Bares R; Dohmen BM; Cremerius U; Fass J; Teusch M; Büll U
    Radiologe; 1996 May; 36(5):435-40. PubMed ID: 8778929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The value of fluorodeoxyglucose positron emission tomography (FDG-PET) in differentiation of pancreatic lesions].
    Voth M; Opfermann T; Gottschild D
    Zentralbl Chir; 2003 May; 128(5):375-8. PubMed ID: 12813634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.